专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US09474770B2 Prophylactic agent and/or therapeutic agent for sepsis 有权
标题翻译：脓毒症的预防剂和/或治疗剂
公开(公告)号：US09474770B2
公开(公告)日：2016-10-25
申请号：US14237407
申请日：2012-08-10
申请人： Kosaku Kinoshita , Katsuhisa Tanjoh , Akihiro Noda , Atsushi Sakurai , Tohru Tanaka , Kiwamu Takahashi , Motowo Nakajima , Fuminori Abe
发明人： Kosaku Kinoshita , Katsuhisa Tanjoh , Akihiro Noda , Atsushi Sakurai , Tohru Tanaka , Kiwamu Takahashi , Motowo Nakajima , Fuminori Abe
IPC分类号： A61K33/26 , A61K31/197 , A61K31/28 , A61K31/295 , A61K45/06
CPC分类号： A61K33/26 , A61K31/197 , A61K31/28 , A61K31/295 , A61K45/06
摘要： The present invention provides a sepsis therapeutic drug useful for prophylaxis and treatment of sepsis. A prophylactic agent and/or a therapeutic agent for sepsis containing 5-aminolevulinic acid (5-ALA) or a derivative thereof or a pharmacologically acceptable salt of 5-ALA or the derivative as an active ingredient is prepared. The prophylactic agent and/or the therapeutic agent preferably contains a metal-containing compound such as ferrous sodium citrate in addition to the ALAs. Preferred examples of the ALAs include ALA; various esters of ALA such as methyl, ethyl, propyl, butyl, and pentyl esters; and hydrochlorides, phosphates, sulfates of ALA and the esters.
摘要翻译：本发明提供了可用于预防和治疗败血症的败血症治疗药物。制备含有5-氨基乙酰丙酸（5-ALA）或其衍生物或5-ALA或其衍生物作为活性成分的药理学上可接受的盐的败血症的预防剂和/或治疗剂。除ALA之外，预防剂和/或治疗剂优选含有含金属的化合物如柠檬酸亚铁。 ALA的优选实例包括ALA; 各种ALA的酯如甲基，乙基，丙基，丁基和戊酯; 和盐酸盐，磷酸盐，ALA的硫酸盐和酯。

2. 发明申请

US20140186464A1 PROPHYLACTIC AGENT AND/OR THERAPEUTIC AGENT FOR SEPSIS 有权
标题翻译：预防剂和/或治疗剂
公开(公告)号：US20140186464A1
公开(公告)日：2014-07-03
申请号：US14237407
申请日：2012-08-10
申请人： Kosaku Kinoshita , Katsuhisa Tanjoh , Akihiro Noda , Atsushi Sakurai , Tohru Tanaka , Kiwamu Takahashi , Motowo Nakajima , Fuminori Abe
发明人： Kosaku Kinoshita , Katsuhisa Tanjoh , Akihiro Noda , Atsushi Sakurai , Tohru Tanaka , Kiwamu Takahashi , Motowo Nakajima , Fuminori Abe
IPC分类号： A61K33/26 , A61K45/06 , A61K31/197
CPC分类号： A61K33/26 , A61K31/197 , A61K31/28 , A61K31/295 , A61K45/06
摘要： The present invention provides a sepsis therapeutic drug useful for prophylaxis and treatment of sepsis. A prophylactic agent and/or a therapeutic agent for sepsis containing 5-aminolevulinic acid (5-ALA) or a derivative thereof or a pharmacologically acceptable salt of 5-ALA or the derivative as an active ingredient is prepared. The prophylactic agent and/or the therapeutic agent preferably contains a metal-containing compound such as ferrous sodium citrate in addition to the ALAs. Preferred examples of the ALAs include ALA; various esters of ALA such as methyl, ethyl, propyl, butyl, and pentyl esters; and hydrochlorides, phosphates, sulfates of ALA and the esters.
摘要翻译：本发明提供了可用于预防和治疗败血症的败血症治疗药物。制备含有5-氨基乙酰丙酸（5-ALA）或其衍生物或5-ALA或其衍生物作为活性成分的药理学上可接受的盐的败血症的预防剂和/或治疗剂。除ALA之外，预防剂和/或治疗剂优选含有含金属的化合物如柠檬酸亚铁。 ALA的优选实例包括ALA; 各种ALA的酯如甲基，乙基，丙基，丁基和戊酯; 和盐酸盐，磷酸盐，ALA的硫酸盐和酯。

3. 发明授权

US09012502B2 Cancer heat therapy-enhancing agent 有权
标题翻译：癌症热疗增强剂
公开(公告)号：US09012502B2
公开(公告)日：2015-04-21
申请号：US13820303
申请日：2011-09-12
申请人： Taku Chibazakura , Tohru Tanaka , Kiwamu Takahashi , Motowo Nakajima , Fuminori Abe
发明人： Taku Chibazakura , Tohru Tanaka , Kiwamu Takahashi , Motowo Nakajima , Fuminori Abe
IPC分类号： A61K31/221 , C07C229/22 , A61K31/197
CPC分类号： C07C229/22 , A61K31/197
摘要： Provided is an enhancer for cancer thermotherapy not combined with photodynamic therapy. Cancer treatment not combined with photodynamic therapy is made available by using, as an enhancer for cancer thermotherapy, 5-aminolevulinic acids represented by formula (1): R2R1NCH2COCH2CH2COR3 (1) [wherein R1 and R2 each independently represent a hydrogen atom, an alkyl group, an acyl group, an alkoxycarbonyl group, an aryl group, or an aralkyl group; and R3 represents a hydroxy group, an alkoxy group, an acyloxy group, an alkoxycarbonyloxy group, an aryloxy group, an aralkyloxy group, or an amino group] or a salt thereof.
摘要翻译：提供了不与光动力疗法结合的癌症热疗的增强剂。通过使用作为癌症热疗的增强剂，可以通过使用由式（1）表示的5-氨基乙酰丙酸获得癌症治疗：R2R1NCH2COCH2CH2COR3（1）[其中R1和R2各自独立地表示氢原子，烷基，酰基，烷氧基羰基，芳基或芳烷基; R3表示羟基，烷氧基，酰氧基，烷氧基羰基氧基，芳氧基，芳烷氧基或氨基）或其盐。

4. 发明授权

US09314443B2 Enhancer of survival of transplanted organ 有权
标题翻译：移植器官生存增强
公开(公告)号：US09314443B2
公开(公告)日：2016-04-19
申请号：US14350488
申请日：2012-09-12
申请人： Ko Rii , Kiwamu Takahashi , Naomi Haga , Fuminori Abe , Tohru Tanaka , Motowo Nakajima , Hidenori Ito
发明人： Ko Rii , Kiwamu Takahashi , Naomi Haga , Fuminori Abe , Tohru Tanaka , Motowo Nakajima , Hidenori Ito
IPC分类号： A61K31/195 , A61K31/265 , A61K31/197 , A61K33/26 , A61K31/22 , A61K31/295 , A61K45/06
CPC分类号： A61K31/197 , A01N1/0226 , A61K31/22 , A61K31/295 , A61K33/26 , A61K35/17 , A61K45/06 , A61K2035/122 , A61K2035/124 , A61K2300/00
摘要： The present invention provides an agent for promoting graft survival which can suppress rejection without use of existing immunosuppressants, an organ preservation solution capable of maintaining the freshness of an organ excised from a donor, and the like. An agent for promoting graft survival or an organ preservation solution is prepared, which comprises 5-aminolevulinic acid (ALA) or a derivative thereof, or a salt of ALA or the derivative and an iron compound as active ingredients. Preferable examples of the ALAs can include ALA and various esters such as methyl ester, ethyl ester, propyl ester, butyl ester, and pentyl ester of ALA, and their hydrochlorides, phosphates, and sulfates. Preferable examples of the iron compound can include sodium ferrous citrate.
摘要翻译：本发明提供了一种用于促进移植物存活的药剂，其可以抑制不使用现有的免疫抑制剂的排斥反应，能够保持从供体排出的器官的新鲜度的器官保存溶液等。制备促进移植物存活的药剂或器官保存溶液，其包含5-氨基乙酰丙酸（ALA）或其衍生物，或ALA或其衍生物和铁化合物的盐作为活性成分。 ALA的优选实例可以包括ALA和各种酯，例如ALA的甲酯，乙酯，丙酯，丁酯和戊酯，以及它们的盐酸盐，磷酸盐和硫酸盐。铁化合物的优选实例可包括柠檬酸亚铁钠。

5. 发明申请

US20140249217A1 ENHANCER OF SURVIVAL OF TRANSPLANTED ORGAN 有权
标题翻译：运输机构存货增值
公开(公告)号：US20140249217A1
公开(公告)日：2014-09-04
申请号：US14350488
申请日：2012-09-12
申请人： Ko Rii , Kiwamu Takahashi , Naomi Haga , Fuminori Abe , Tohru Tanaka , Motowo Nakajima , Hidenori Ito
发明人： Ko Rii , Kiwamu Takahashi , Naomi Haga , Fuminori Abe , Tohru Tanaka , Motowo Nakajima , Hidenori Ito
IPC分类号： A61K31/197 , A61K31/295
CPC分类号： A61K31/197 , A01N1/0226 , A61K31/22 , A61K31/295 , A61K33/26 , A61K35/17 , A61K45/06 , A61K2035/122 , A61K2035/124 , A61K2300/00
摘要： The present invention provides an agent for promoting graft survival which can suppress rejection without use of existing immunosuppressants, an organ preservation solution capable of maintaining the freshness of an organ excised from a donor, and the like. An agent for promoting graft survival or an organ preservation solution is prepared, which comprises 5-aminolevulinic acid (ALA) or a derivative thereof, or a salt of ALA or the derivative and an iron compound as active ingredients. Preferable examples of the ALAs can include ALA and various esters such as methyl ester, ethyl ester, propyl ester, butyl ester, and pentyl ester of ALA, and their hydrochlorides, phosphates, and sulfates. Preferable examples of the iron compound can include sodium ferrous citrate.
摘要翻译：本发明提供了一种用于促进移植物存活的药剂，其可以抑制不使用现有的免疫抑制剂的排斥反应，能够保持从供体排出的器官的新鲜度的器官保存溶液等。制备促进移植物存活的药物或器官保存溶液，其包含5-氨基乙酰丙酸（ALA）或其衍生物，或ALA或其衍生物和铁化合物的盐作为活性成分。 ALA的优选实例可以包括ALA和各种酯，例如ALA的甲酯，乙酯，丙酯，丁酯和戊酯，以及它们的盐酸盐，磷酸盐和硫酸盐。铁化合物的优选实例可包括柠檬酸亚铁钠。

6. 发明申请

US20130158293A1 CANCER HEAT THERAPY-ENHANCING AGENT 有权
标题翻译：癌症治疗增强剂
公开(公告)号：US20130158293A1
公开(公告)日：2013-06-20
申请号：US13820303
申请日：2011-09-12
申请人： Taku Chibazakura , Tohru Tanaka , Kiwamu Takahashi , Motowo Nakajima , Fuminori Abe
发明人： Taku Chibazakura , Tohru Tanaka , Kiwamu Takahashi , Motowo Nakajima , Fuminori Abe
IPC分类号： C07C229/22
CPC分类号： C07C229/22 , A61K31/197
摘要： Provided is an enhancer for cancer thermotherapy not combined with photodynamic therapy. Cancer treatment not combined with photodynamic therapy is made available by using, as an enhancer for cancer thermotherapy, 5-aminolevulinic acids represented by formula (1): R2R1NCH2COCH2CH2COR3 (1) [wherein R1 and R2 each independently represent a hydrogen atom, an alkyl group, an acyl group, an alkoxycarbonyl group, an aryl group, or an aralkyl group; and R3 represents a hydroxy group, an alkoxy group, an acyloxy group, an alkoxycarbonyloxy group, an aryloxy group, an aralkyloxy group, or an amino group] or a salt thereof.
摘要翻译：提供了不与光动力疗法结合的癌症热疗的增强剂。通过使用作为癌症热疗的增强剂，可以通过使用由式（1）表示的5-氨基乙酰丙酸获得癌症治疗：R2R1NCH2COCH2CH2COR3（1）[其中R1和R2各自独立地表示氢原子，烷基，酰基，烷氧基羰基，芳基或芳烷基; R3表示羟基，烷氧基，酰氧基，烷氧基羰基氧基，芳氧基，芳烷氧基或氨基）或其盐。

7. 发明申请

US20130108710A1 Antimalarial Drug Which Contains 5-Aminolevulinic Acid or Derivative Thereof as Active Ingredient 有权
公开(公告)号：US20130108710A1
公开(公告)日：2013-05-02
申请号：US13698090
申请日：2011-05-18
申请人： Tohru Tanaka , Satofumi Kawata , Takeo Kohda , Motowo Nakajima , Kiyoshi Kita
发明人： Tohru Tanaka , Satofumi Kawata , Takeo Kohda , Motowo Nakajima , Kiyoshi Kita
IPC分类号： A61K31/197 , A61K33/26
CPC分类号： A61K31/197 , A61K9/4866 , A61K31/221 , A61K33/06 , A61K33/26 , A61K33/30 , A61K45/06 , Y02A50/411 , A61K2300/00
摘要： Provided is an antimalarial drug which is useful for prevention and treatment of infectious diseases caused by malaria parasites. A preventive and/or therapeutic agent for malaria, which contains, as an active ingredient, 5-aminolevulinic acid (ALA), a derivative thereof, or a pharmacologically acceptable salt thereof, is used.

8. 发明授权

US09089530B2 Antimalarial drug which contains 5-aminolevulinic acid or derivative thereof as active ingredient 有权
标题翻译：含有5-氨基乙酰丙酸或其衍生物作为活性成分的抗疟药
公开(公告)号：US09089530B2
公开(公告)日：2015-07-28
申请号：US13698090
申请日：2011-05-18
申请人： Tohru Tanaka , Satofumi Kawata , Takeo Kohda , Motowo Nakajima , Kiyoshi Kita
发明人： Tohru Tanaka , Satofumi Kawata , Takeo Kohda , Motowo Nakajima , Kiyoshi Kita
IPC分类号： A61K31/197 , A61K33/26 , A61K45/06 , A61K31/221 , A61K33/06 , A61K33/30 , A61K9/48
CPC分类号： A61K31/197 , A61K9/4866 , A61K31/221 , A61K33/06 , A61K33/26 , A61K33/30 , A61K45/06 , Y02A50/411 , A61K2300/00
摘要： Provided is an antimalarial drug which is useful for prevention and treatment of infectious diseases caused by malaria parasites. A preventive and/or therapeutic agent for malaria, which contains, as an active ingredient, 5-aminolevulinic acid (ALA), a derivative thereof, or a pharmacologically acceptable salt thereof, is used.
摘要翻译：是一种抗疟药，可用于预防和治疗疟疾寄生虫引起的传染病。使用含有5-氨基乙酰丙酸（ALA），其衍生物或其药理学上可接受的盐作为有效成分的疟疾预防和/或治疗剂。

9. 发明申请

US20130217913A1 Antimalarial Drug Comprising Alaremycin or Derivative Thereof as Active Ingredient 有权
标题翻译：包括阿拉霉素或其衍生物的抗疟药物作为活性成分
公开(公告)号：US20130217913A1
公开(公告)日：2013-08-22
申请号：US13883038
申请日：2011-11-09
申请人： Masaaki Wachi , Shigeharu Sato , Tohru Tanaka , Kiwamu Takahashi
发明人： Masaaki Wachi , Shigeharu Sato , Tohru Tanaka , Kiwamu Takahashi
IPC分类号： A61K31/197 , A61K31/16 , A61K31/221
CPC分类号： A61K31/197 , A61K9/0019 , A61K9/107 , A61K9/2018 , A61K9/2027 , A61K31/16 , A61K31/221 , Y02A50/411
摘要： Provided is a preventive and/or therapeutic agent for malaria, comprising, as an active ingredient, 5-acetamido-4-oxo-5-hexenoic acid (Alaremycin) or a derivative thereof. A preventive and/or therapeutic agent for malaria is used which comprises, as an active ingredient, Alaremycin or a derivative thereof represented by formula (I) (wherein R1 represents a hydroxy group, an amino group, or a substituted or unsubstituted straight chain or branched alkoxy group or alkylamino group having 1 to 8 carbons; R2 represents hydrogen, a substituted or unsubstituted straight chain or branched alkyl group having 1 to 8 carbons, or a substituted or unsubstituted aromatic group having 4 to 10 carbons; and R3 represents hydrogen or a methyl group).
摘要翻译：本发明提供疟疾的预防和/或治疗剂，其包含作为活性成分的5-乙酰氨基-4-氧代-5-己烯酸（阿拉霉霉素）或其衍生物。使用疟疾的预防和/或治疗剂，其包含作为活性成分的由式（I）表示的阿拉霉素或其衍生物（其中R 1表示羟基，氨基或取代或未取代的直链或支链烷氧基或碳原子数为1〜8的烷基氨基; R2表示氢，取代或未取代的碳原子数1〜8的直链或支链烷基或取代或未取代的碳原子数4〜10的芳基，R3表示氢或甲基）。

10. 发明授权

US09550073B2 Therapeutic agent for allergic rhinitis 有权
标题翻译：过敏性鼻炎治疗剂
公开(公告)号：US09550073B2
公开(公告)日：2017-01-24
申请号：US14125744
申请日：2012-06-15
申请人： Tohru Tanaka , Katsushi Inoue , Kiwamu Takahashi , Takuya Ishii , Tsutomu Numata , Mariko Shibuya , Takeshi Suzuki
发明人： Tohru Tanaka , Katsushi Inoue , Kiwamu Takahashi , Takuya Ishii , Tsutomu Numata , Mariko Shibuya , Takeshi Suzuki
IPC分类号： A61N5/06 , A61K9/06 , A61K41/00 , A61K9/00
CPC分类号： A61N5/062 , A61K9/0043 , A61K9/06 , A61K41/0061 , F04C2270/0421
摘要： Provided is a therapeutic agent capable of treating allergic rhinitis in a safe, simple, and noninvasive manner substantially without side effects and physical distress to patients. Provided is a therapeutic agent for allergic rhinitis for 5-aminolevulinic acid-based photodynamic therapy (ALA-PDT) comprising 5-aminolevulinic acid (ALA) or a derivative thereof, or a salt of the 5-aminolevulinic acid or the derivative as an active ingredient, and used in ALA-PDT in which light having a wavelength of 400 nm to 700 nm is irradiated; and particularly provided is a therapeutic agent for allergic rhinitis in a locally applied solution form, a water-soluble ointment-dissolved form, a jelly-dissolved form, or the like. The therapeutic agent does not require the conduct of 5-aminolevulinic acid-based photodynamic diagnosis (ALA-PDD) for detecting a site of protoporphyrin IX (PpIX) accumulation radiating light having a wavelength of 610 nm to 650 nm under irradiation of excitation light having a wavelength of 380 nm to 420 nm before ALA-PDT.
摘要翻译：本发明提供能够以安全，简单，无创的方式治疗过敏性鼻炎的治疗剂，其基本上无副作用和对患者的身体伤害。本发明提供了包含5-氨基乙酰丙酸（ALA）或其衍生物的5-氨基乙酰丙酸类光动力治疗（ALA-PDT）或5-氨基乙酰丙酸或其衍生物的活性成分的过敏性鼻炎的治疗剂成分，并用于其中照射波长为400nm至700nm的光的ALA-PDT中; 并且特别提供了局部施用的溶液形式的过敏性鼻炎的治疗剂，溶于水的软膏溶解形式，果冻溶解形式等。治疗剂不需要进行基于5-氨基乙酰丙酸的光动力学诊断（ALA-PDD），用于检测在具有610nm至650nm的波长的照射下发射具有波长为610nm至650nm的光的原卟啉IX（PpIX）积累的位点，在ALA-PDT之前的波长为380nm至420nm。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式